Loxapine Capsules
GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross contamination
Most common reason: Labeling / mix-up (6 of these recalls)
Recalls are matched by product description. A recall usually affects specific lots, not every package of Loxapine. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.
GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross contamination
GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross contamination
CGMP Deviations
CGMP Deviations
Labeling: Label Mixup: LOXAPINE, Capsule, 5 mg may have potentially been mislabeled as the following drug: SERTRALINE HCL, Tablet, 50 mg, NDC 16714061204, Pedigree: AD46426_1, EXP: 5/15/2014.
Labeling: Incorrect or Missing Package Insert: An outdated version of a patient outsert was used when packaged.
Labeling: Incorrect or Missing Package Insert: An outdated version of a patient outsert was used when packaged.
Labeling: Incorrect or Missing Package Insert: An outdated version of a patient outsert was used when packaged.
Labeling: Incorrect or Missing Package Insert: An outdated version of a patient outsert was used when packaged.
Labeling: Incorrect or Missing Package Insert: An outdated version of a patient outsert was used when packaged.
Free recall alerts
Tell us what you take. When FDA posts a recall announcement or classifies a recall for one of your medications, we email you in plain English, with what to check. No account needed.